{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:51:53Z","timestamp":1793922713850,"version":"4.8.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41591-023-02567-2","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:01:56Z","timestamp":1696852916000},"page":"2424-2437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Recent successes in heart failure treatment"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0018","authenticated-orcid":false,"given":"Carolyn S. P.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5446-9969","authenticated-orcid":false,"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7987-4768","authenticated-orcid":false,"given":"Jennifer E.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder L.","family":"Myhre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f8rn","family":"Omland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"2567_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD Disease","year":"2018","unstructured":"Disease, G. B. D., Injury, I. & Prevalence, C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789\u20131858 (2018).","journal-title":"Lancet"},{"key":"2567_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","volume":"63","author":"AP Ambrosy","year":"2014","unstructured":"Ambrosy, A. P. et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J. Am. Coll. Cardiol. 63, 1123\u20131133 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ehf2.12021","volume":"1","author":"MR Cowie","year":"2014","unstructured":"Cowie, M. R. et al. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail. 1, 110\u2013145 (2014).","journal-title":"ESC Heart Fail."},{"key":"2567_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ejhf.822","volume":"19","author":"MA Mamas","year":"2017","unstructured":"Mamas, M. A. et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur. J. Heart Fail. 19, 1095\u20131104 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"2567_CR5","unstructured":"Braunwald E. Heart Disease: a Textbook of Cardiovascular Medicine 4th ed. (WB Saunders, 1992)."},{"key":"2567_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt, B. et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J. Card. Fail. 27, 387\u2013413 (2021).","journal-title":"J. Card. Fail."},{"key":"2567_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"2567_CR8","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, 1757\u20131780 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan, T. E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251\u2013259 (2006).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR10","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay, S. M., Roger, V. L. & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 14, 591\u2013602 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"2567_CR11","unstructured":"US Food and Drug Administration. ENTRESTO (sacubitril and valsartan) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207620s018lbl.pdf (2021)."},{"key":"2567_CR12","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao, C. W. et al. Heart Disease and Stroke Statistics\u20142022 update: a report from the American Heart Association. Circulation 145, e153\u2013e639 (2022).","journal-title":"Circulation"},{"key":"2567_CR13","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese, G. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 118, 3272\u20133287 (2023).","journal-title":"Cardiovasc. Res."},{"key":"2567_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","volume":"128","author":"VL Roger","year":"2021","unstructured":"Roger, V. L. Epidemiology of heart failure: a contemporary perspective. Circ. Res. 128, 1421\u20131434 (2021).","journal-title":"Circ. Res."},{"key":"2567_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad, N. et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391, 572\u2013580 (2018).","journal-title":"Lancet"},{"key":"2567_CR16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","volume":"6","author":"CW Tsao","year":"2018","unstructured":"Tsao, C. W. et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 6, 678\u2013685 (2018).","journal-title":"JACC Heart Fail."},{"key":"2567_CR17","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/ehjqcco\/qcab073","volume":"8","author":"A Arulmurugananthavadivel","year":"2022","unstructured":"Arulmurugananthavadivel, A. et al. Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. Eur. Heart J. Qual. Care Clin. Outcomes 8, 750\u2013760 (2022).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"2567_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jchf.2015.03.013","volume":"3","author":"CJ Rush","year":"2015","unstructured":"Rush, C. J. et al. Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC Heart Fail. 3, 603\u2013614 (2015).","journal-title":"JACC Heart Fail."},{"key":"2567_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609758","volume":"377","author":"L Shen","year":"2017","unstructured":"Shen, L. et al. Declining risk of sudden death in heart failure. N. Engl. J. Med. 377, 41\u201351 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR20","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer, M. A., Shah, A. M. & Borlaug, B. A. Heart failure with preserved ejection fraction in perspective. Circ. Res. 124, 1598\u20131617 (2019).","journal-title":"Circ. Res."},{"key":"2567_CR21","doi-asserted-by":"publisher","first-page":"e007264","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","volume":"13","author":"A Nayak","year":"2020","unstructured":"Nayak, A., Hicks, A. J. & Morris, A. A. Understanding the complexity of heart failure risk and treatment in black patients. Circ. Heart Fail. 13, e007264 (2020).","journal-title":"Circ. Heart Fail."},{"key":"2567_CR22","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","volume":"8","author":"J Tromp","year":"2020","unstructured":"Tromp, J. et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob. Health 8, e411\u2013e422 (2020).","journal-title":"Lancet Glob. Health"},{"key":"2567_CR23","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","volume":"8","author":"KF Docherty","year":"2020","unstructured":"Docherty, K. F., Vaduganathan, M., Solomon, S. D. & McMurray, J. J. V. Sacubitril\/valsartan: neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 8, 800\u2013810 (2020).","journal-title":"JACC Heart Fail."},{"key":"2567_CR25","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon, S. D. et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N. Engl. J. Med. 381, 1609\u20131620 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon, S. D. et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141, 352\u2013361 (2020).","journal-title":"Circulation"},{"key":"2567_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire, D. K. et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 6, 148\u2013158 (2021).","journal-title":"JAMA Cardiol."},{"key":"2567_CR28","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR30","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR31","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jacc.2022.07.021","volume":"80","author":"JW Cunningham","year":"2022","unstructured":"Cunningham, J. W. et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J. Am. Coll. Cardiol. 80, 1302\u20131310 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod, M. N. et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation 141, 90\u201399 (2020).","journal-title":"Circulation"},{"key":"2567_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761\u2013772 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"2567_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","volume":"20","author":"M Packer","year":"2023","unstructured":"Packer, M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat. Rev. Cardiol. 20, 443\u2013462 (2023).","journal-title":"Nat. Rev. Cardiol."},{"key":"2567_CR35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan, M. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400, 757\u2013767 (2022).","journal-title":"Lancet"},{"key":"2567_CR36","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","volume":"5","author":"NS Bassi","year":"2020","unstructured":"Bassi, N. S., Ziaeian, B., Yancy, C. W. & Fonarow, G. C. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol. 5, 948\u2013951 (2020).","journal-title":"JAMA Cardiol."},{"key":"2567_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy, G. H. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225\u2013237 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR38","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow, M. R. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med. 350, 2140\u20132150 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR39","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland, J. G. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539\u20131549 (2005).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR40","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss, A. J. et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N. Engl. J. Med. 361, 1329\u20131338 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR41","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","volume":"363","author":"AS Tang","year":"2010","unstructured":"Tang, A. S. et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J. Med. 363, 2385\u20132395 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR42","doi-asserted-by":"crossref","unstructured":"Clephas, P. R. D. et al. Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials. Eur. Heart J. ehad346 (2023).","DOI":"10.1093\/eurheartj\/ehad346"},{"key":"2567_CR43","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1136\/hrt.2011.225789","volume":"97","author":"A Rossi","year":"2011","unstructured":"Rossi, A. et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97, 1675\u20131680 (2011).","journal-title":"Heart"},{"key":"2567_CR44","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone, G. W. et al. Transcatheter mitral-valve repair in patients with heart failure. N. Engl. J. Med. 379, 2307\u20132318 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR45","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"JF Obadia","year":"2018","unstructured":"Obadia, J. F. et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N. Engl. J. Med. 379, 2297\u20132306 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jcmg.2018.11.006","volume":"12","author":"PA Grayburn","year":"2019","unstructured":"Grayburn, P. A., Sannino, A. & Packer, M. Proportionate and disproportionate Functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc. Imaging 12, 353\u2013362 (2019).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"2567_CR47","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMoa012175","volume":"345","author":"EA Rose","year":"2001","unstructured":"Rose, E. A. et al. Long-term use of a left ventricular assist device for end-stage heart failure. N. Engl. J. Med. 345, 1435\u20131443 (2001).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR48","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","volume":"361","author":"MS Slaughter","year":"2009","unstructured":"Slaughter, M. S. et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N. Engl. J. Med. 361, 2241\u20132251 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR49","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.2022.16197","volume":"328","author":"MR Mehra","year":"2022","unstructured":"Mehra, M. R. et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA 328, 1233\u20131242 (2022).","journal-title":"JAMA"},{"key":"2567_CR50","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1016\/j.jtcvs.2019.09.080","volume":"159","author":"OK Jawitz","year":"2020","unstructured":"Jawitz, O. K. et al. Increasing the United States heart transplant donor pool with donation after circulatory death. J. Thorac. Cardiovasc. Surg. 159, e307\u2013e309 (2020).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"2567_CR51","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.healun.2017.10.021","volume":"36","author":"S Messer","year":"2017","unstructured":"Messer, S. et al. Outcome after heart transplantation from donation after circulatory-determined death donors. J. Heart Lung Transplant. 36, 1311\u20131318 (2017).","journal-title":"J. Heart Lung Transplant."},{"key":"2567_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.xjtc.2021.12.014","volume":"12","author":"OK Jawitz","year":"2022","unstructured":"Jawitz, O. K., Bryner, B. S., Schroder, J. N. & DeVore, A. D. Donation after circulatory death heart transplantation in the United States: an early report of donor characteristics. JTCVS Tech. 12, 104\u2013107 (2022).","journal-title":"JTCVS Tech."},{"key":"2567_CR53","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa2212438","volume":"388","author":"JN Schroder","year":"2023","unstructured":"Schroder, J. N. et al. Transplantation outcomes with donor hearts after circulatory death. N. Engl. J. Med. 388, 2121\u20132131 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR54","first-page":"e558","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen, S. R. et al. 2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: a Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142, e558\u2013e631 (2020).","journal-title":"Circulation"},{"key":"2567_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","volume":"81","author":"MS Maron","year":"2023","unstructured":"Maron, M. S. et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 81, 34\u201345 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR56","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto, I. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396, 759\u2013769 (2020).","journal-title":"Lancet"},{"key":"2567_CR57","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson, M. M. et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation 142, e7\u2013e22 (2020).","journal-title":"Circulation"},{"key":"2567_CR58","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan, M. et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J. Am. Coll. Cardiol. 68, 1014\u20131020 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane, T. et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140, 16\u201326 (2019).","journal-title":"Circulation"},{"key":"2567_CR60","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N. Engl. J. Med. 379, 1007\u20131016 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR61","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene, S. J. et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF Registry. J. Am. Coll. Cardiol. 72, 351\u2013366 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jchf.2018.10.010","volume":"7","author":"HP Brunner-La Rocca","year":"2019","unstructured":"Brunner-La Rocca, H. P. et al. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: the CHECK-HF Registry. JACC Heart Fail. 7, 13\u201321 (2019).","journal-title":"JACC Heart Fail."},{"key":"2567_CR63","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","volume":"6","author":"TK Teng","year":"2018","unstructured":"Teng, T. K. et al. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob. Health 6, e1008\u2013e1018 (2018).","journal-title":"Lancet Glob. Health"},{"key":"2567_CR64","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez, E. J. et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N. Engl. J. Med. 380, 539\u2013548 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR65","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors, A. A. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. 28, 568\u2013574 (2022).","journal-title":"Nat. Med."},{"key":"2567_CR66","doi-asserted-by":"crossref","unstructured":"Vaduganathan, M. et al. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur. Heart J. 44, 2982\u20132993 (2023).","DOI":"10.1093\/eurheartj\/ehad344"},{"key":"2567_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117\u2013128 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR68","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa, A. et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400, 1938\u20131952 (2022).","journal-title":"Lancet"},{"key":"2567_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ahj.2017.04.001","volume":"189","author":"TC Randolph","year":"2017","unstructured":"Randolph, T. C. et al. Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. Am. Heart J. 189, 48\u201358 (2017).","journal-title":"Am. Heart J."},{"key":"2567_CR70","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/eurjhf\/hfp149","volume":"11","author":"DJ van Veldhuisen","year":"2009","unstructured":"van Veldhuisen, D. J. et al. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur. J. Heart Fail. 11, 1143\u20131151 (2009).","journal-title":"Eur. J. Heart Fail."},{"key":"2567_CR71","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/europace\/euu205","volume":"17","author":"C Linde","year":"2015","unstructured":"Linde, C. et al. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace 17, 424\u2013431 (2015).","journal-title":"Europace"},{"key":"2567_CR72","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jchf.2017.02.018","volume":"5","author":"KJ Lyons","year":"2017","unstructured":"Lyons, K. J. et al. Impact of current versus previous cardiac resynchronization therapy guidelines on the proportion of patients with heart failure eligible for therapy. JACC Heart Fail. 5, 388\u2013392 (2017).","journal-title":"JACC Heart Fail."},{"key":"2567_CR73","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.121.054034","volume":"144","author":"GM Felker","year":"2021","unstructured":"Felker, G. M. et al. Implantable cardioverter-defibrillator eligibility after initiation of sacubitril\/valsartan in chronic heart failure: insights from PROVE-HF. Circulation 144, 180\u2013182 (2021).","journal-title":"Circulation"},{"key":"2567_CR74","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2026141","volume":"385","author":"DW Kitzman","year":"2021","unstructured":"Kitzman, D. W. et al. Physical rehabilitation for older patients hospitalized for heart failure. N. Engl. J. Med. 385, 203\u2013216 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR75","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1001\/jama.2020.21395","volume":"324","author":"A Agarwal","year":"2020","unstructured":"Agarwal, A., Yancy, C. W. & Huffman, M. D. Improving care for heart failure with reduced ejection fraction\u2014a potential polypill-based strategy. JAMA 324, 2259\u20132260 (2020).","journal-title":"JAMA"},{"key":"2567_CR76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.5334\/gh.1215","volume":"18","author":"A Vijay","year":"2023","unstructured":"Vijay, A. et al. Polypill eligibility for patients with heart failure with reduced ejection fraction in the ASIAN-HF registry: a cross-sectional analysis. Glob. Heart 18, 33 (2023).","journal-title":"Glob. Heart"},{"key":"2567_CR77","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S0002-9149(02)02464-5","volume":"90","author":"TJ Wang","year":"2002","unstructured":"Wang, T. J. et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol. 90, 254\u2013258 (2002).","journal-title":"Am. J. Cardiol."},{"key":"2567_CR78","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1001\/jamacardio.2022.0680","volume":"7","author":"PL Myhre","year":"2022","unstructured":"Myhre, P. L. et al. Sex and race differences in N-terminal pro-B-type natriuretic peptide concentration and absolute risk of heart failure in the community. JAMA Cardiol. 7, 623\u2013631 (2022).","journal-title":"JAMA Cardiol."},{"key":"2567_CR79","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jacc.2005.05.057","volume":"46","author":"CW Knudsen","year":"2005","unstructured":"Knudsen, C. W. et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J. Am. Coll. Cardiol. 46, 838\u2013844 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR80","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2215\/CJN.00850208","volume":"3","author":"R Tagore","year":"2008","unstructured":"Tagore, R. et al. Natriuretic peptides in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3, 1644\u20131651 (2008).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2567_CR81","doi-asserted-by":"publisher","first-page":"e018689","DOI":"10.1161\/JAHA.120.018689","volume":"10","author":"V Parcha","year":"2021","unstructured":"Parcha, V. et al. Obesity and serial NT-proBNP Levels in guided medical therapy for heart failure with reduced ejection fraction: insights from the GUIDE-IT trial. J. Am. Heart Assoc. 10, e018689 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"2567_CR82","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1136\/heartjnl-2015-307782","volume":"101","author":"SH Kang","year":"2015","unstructured":"Kang, S. H. et al. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart 101, 1881\u20131888 (2015).","journal-title":"Heart"},{"key":"2567_CR83","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1093\/eurheartj\/ehab911","volume":"43","author":"FH Verbrugge","year":"2022","unstructured":"Verbrugge, F. H. et al. Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality. Eur. Heart J. 43, 1941\u20131951 (2022).","journal-title":"Eur. Heart J."},{"key":"2567_CR84","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1016\/S2214-109X(17)30196-1","volume":"5","author":"H Dokainish","year":"2017","unstructured":"Dokainish, H. et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob. Health 5, e665\u2013e672 (2017).","journal-title":"Lancet Glob. Health"},{"key":"2567_CR85","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11897-021-00524-z","volume":"18","author":"A Agarwal","year":"2021","unstructured":"Agarwal, A. et al. Guideline-directed medical therapy in females with heart failure with reduced ejection fraction. Curr. Heart Fail. Rep. 18, 284\u2013289 (2021).","journal-title":"Curr. Heart Fail. Rep."},{"key":"2567_CR86","doi-asserted-by":"publisher","first-page":"e008971","DOI":"10.1161\/CIRCHEARTFAILURE.121.008971","volume":"15","author":"A Agarwal","year":"2022","unstructured":"Agarwal, A., Husain, M., Datta, B., Kishore, S. & Huffman, M. Access to heart failure medicines in low and middle-income countries: an analysis of essential medicines lists, availability, price and affordability. Circ. Heart Fail. 15, e008971 (2022).","journal-title":"Circ. Heart Fail."},{"key":"2567_CR87","doi-asserted-by":"publisher","first-page":"e006962","DOI":"10.1161\/CIRCOUTCOMES.120.006962","volume":"14","author":"TK Teng","year":"2021","unstructured":"Teng, T. K. et al. Socioeconomic status and outcomes in heart failure with reduced ejection fraction from Asia. Circ. Cardiovasc Qual. Outcomes 14, e006962 (2021).","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"2567_CR88","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/eurjpc\/zwaa005","volume":"28","author":"J Andersen","year":"2021","unstructured":"Andersen, J. et al. The mediating role of effective treatments in the relationship between income level and survival in patients with heart failure: a sex- and cohabitation-stratified study. Eur. J. Prev. Cardiol. 28, 78\u201386 (2021).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2567_CR89","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","volume":"40","author":"CSP Lam","year":"2019","unstructured":"Lam, C. S. P. et al. Sex differences in heart failure. Eur. Heart J. 40, 3859\u20133868c (2019).","journal-title":"Eur. Heart J."},{"key":"2567_CR90","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","volume":"6","author":"N Savji","year":"2018","unstructured":"Savji, N. et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail. 6, 701\u2013709 (2018).","journal-title":"JACC Heart Fail."},{"key":"2567_CR91","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jacc.2022.02.020","volume":"79","author":"ES Lau","year":"2022","unstructured":"Lau, E. S. et al. Infertility and risk of heart failure in the women\u2019s health Initiative. J. Am. Coll. Cardiol. 79, 1594\u20131603 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR92","doi-asserted-by":"crossref","unstructured":"Sarma, A. A. et al. Multiple prior live births are associated with cardiac remodeling and heart failure risk in women. J. Card. Fail. 29, 1032\u20131042 (2023).","DOI":"10.1016\/j.cardfail.2022.12.014"},{"key":"2567_CR93","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2021.09.1360","volume":"78","author":"D Williams","year":"2021","unstructured":"Williams, D. et al. Preeclampsia predicts risk of hospitalization for heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 78, 2281\u20132290 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR94","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.119.043594","volume":"141","author":"X Jin","year":"2020","unstructured":"Jin, X. et al. Women\u2019s participation in cardiovascular clinical trials from 2010 to 2017. Circulation 141, 540\u2013548 (2020).","journal-title":"Circulation"},{"key":"2567_CR95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jacc.2018.09.081","volume":"73","author":"P Dewan","year":"2019","unstructured":"Dewan, P. et al. Differential impact of heart failure with reduced ejection fraction on men and women. J. Am. Coll. Cardiol. 73, 29\u201340 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR96","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon, S. D. et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur. Heart J. 37, 455\u2013462 (2016).","journal-title":"Eur. Heart J."},{"key":"2567_CR97","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson, M. M. et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol. 81, 1835\u20131878 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR98","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.drudis.2020.10.019","volume":"26","author":"SS Wu","year":"2021","unstructured":"Wu, S. S. et al. Reviving an R&D pipeline: a step change in the phase II success rate. Drug Discov. Today 26, 308\u2013314 (2021).","journal-title":"Drug Discov. Today"},{"key":"2567_CR99","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 382, 1883\u20131893 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR100","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","volume":"8","author":"JA Ezekowitz","year":"2020","unstructured":"Ezekowitz, J. A. et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 8, 931\u2013939 (2020).","journal-title":"JACC Heart Fail."},{"key":"2567_CR101","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","volume":"6","author":"CSP Lam","year":"2021","unstructured":"Lam, C. S. P. et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 6, 706\u2013712 (2021).","journal-title":"JAMA Cardiol."},{"key":"2567_CR102","doi-asserted-by":"publisher","first-page":"e008100","DOI":"10.1161\/CIRCHEARTFAILURE.120.008100","volume":"14","author":"RJ Mentz","year":"2021","unstructured":"Mentz, R. J. et al. Randomized placebo-controlled trial of ferric carboxymaltose in heart failure with iron deficiency: rationale and design. Circ. Heart Fail. 14, e008100 (2021).","journal-title":"Circ. Heart Fail."},{"key":"2567_CR103","doi-asserted-by":"crossref","unstructured":"Vukadinovic, D. et al. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta-analysis. Clin. Res. Cardiol. 112, 954\u2013966 (2023).","DOI":"10.1007\/s00392-023-02207-2"},{"key":"2567_CR104","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra, P. R. et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400, 2199\u20132209 (2022).","journal-title":"Lancet"},{"key":"2567_CR105","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski, P. et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396, 1895\u20131904 (2020).","journal-title":"Lancet"},{"key":"2567_CR106","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ejhf.1452","volume":"21","author":"U Bavendiek","year":"2019","unstructured":"Bavendiek, U. et al. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. Eur. J. Heart Fail. 21, 676\u2013684 (2019).","journal-title":"Eur. J. Heart Fail."},{"key":"2567_CR107","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/eurheartj\/ehac197","volume":"43","author":"P van der Meer","year":"2022","unstructured":"van der Meer, P., Rienstra, M. & van Veldhuisen, D. J. A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin? Eur. Heart J. 43, 2221\u20132223 (2022).","journal-title":"Eur. Heart J."},{"key":"2567_CR108","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131, 34\u201342 (2015).","journal-title":"Circulation"},{"key":"2567_CR109","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"2567_CR110","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","volume":"128","author":"WJ Paulus","year":"2021","unstructured":"Paulus, W. J. & Zile, M. R. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ. Res. 128, 1451\u20131467 (2021).","journal-title":"Circ. Res."},{"key":"2567_CR111","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","volume":"117","author":"PM Ridker","year":"2021","unstructured":"Ridker, P. M. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 117, e138\u2013e140 (2021).","journal-title":"Cardiovasc Res."},{"key":"2567_CR112","doi-asserted-by":"publisher","first-page":"28","DOI":"10.7570\/jomes22012","volume":"31","author":"HN Jung","year":"2022","unstructured":"Jung, H. N. & Jung, C. H. The upcoming weekly tides (semaglutide vs. tirzepatide) against obesity: STEP or SURPASS? J. Obes. Metab. Syndr. 31, 28\u201336 (2022).","journal-title":"J. Obes. Metab. Syndr."},{"key":"2567_CR113","doi-asserted-by":"crossref","unstructured":"Lam, C. S. P. et al. Myeloperoxidase inhibition in heart failure with preserved or mildly reduced ejection fraction: SATELLITE Trial Results. J. Card. Fail. S1071-9164, 00142-2 (2023).","DOI":"10.1016\/j.cardfail.2023.04.003"},{"key":"2567_CR114","doi-asserted-by":"crossref","unstructured":"Kosiborod, M. N. et al. Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail. 11, 1000\u20131010 (2023).","DOI":"10.1016\/j.jchf.2023.05.010"},{"key":"2567_CR115","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jacc.2021.06.040","volume":"78","author":"M Fudim","year":"2021","unstructured":"Fudim, M. et al. Device therapy in chronic heart failure: JACC state-of-the-art review. J. Am. Coll. Cardiol. 78, 931\u2013956 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR116","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.jacc.2021.04.070","volume":"77","author":"CSP Lam","year":"2021","unstructured":"Lam, C. S. P. & Solomon, S. D. Classification of heart failure according to ejection fraction: JACC review topic of the week. J. Am. Coll. Cardiol. 77, 3217\u20133225 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR117","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/eurheartj\/ehv510","volume":"37","author":"M Cikes","year":"2016","unstructured":"Cikes, M. & Solomon, S. D. Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur. Heart J. 37, 1642\u20131650 (2016).","journal-title":"Eur. Heart J."},{"key":"2567_CR118","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0002-8703(03)00248-5","volume":"146","author":"JH McGowan","year":"2003","unstructured":"McGowan, J. H. & Cleland, J. G. Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. Am. Heart J. 146, 388\u2013397 (2003).","journal-title":"Am. Heart J."},{"key":"2567_CR119","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","volume":"131","author":"SJ Shah","year":"2015","unstructured":"Shah, S. J. et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131, 269\u2013279 (2015).","journal-title":"Circulation"},{"key":"2567_CR120","doi-asserted-by":"publisher","first-page":"e1002541","DOI":"10.1371\/journal.pmed.1002541","volume":"15","author":"J Tromp","year":"2018","unstructured":"Tromp, J. et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med. 15, e1002541 (2018).","journal-title":"PLoS Med."},{"key":"2567_CR121","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1093\/cvr\/cvac179","volume":"118","author":"AE Peters","year":"2023","unstructured":"Peters, A. E. et al. Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. Cardiovasc. Res. 118, 3403\u20133415 (2023).","journal-title":"Cardiovasc. Res."},{"key":"2567_CR122","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1056\/NEJMoa0805299","volume":"361","author":"T Omland","year":"2009","unstructured":"Omland, T. et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med. 361, 2538\u20132547 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR123","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jacc.2007.03.038","volume":"50","author":"T Omland","year":"2007","unstructured":"Omland, T. et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial. J. Am. Coll. Cardiol. 50, 205\u2013214 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR124","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1001\/jamacardio.2023.0019","volume":"8","author":"TA Zelniker","year":"2023","unstructured":"Zelniker, T. A. et al. Association of cardiac biomarkers with major adverse cardiovascular events in high-risk patients with diabetes: a secondary analysis of the DECLARE-TIMI 58 trial. JAMA Cardiol. 8, 503\u2013509 (2023).","journal-title":"JAMA Cardiol."},{"key":"2567_CR125","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.2013.7588","volume":"310","author":"M Ledwidge","year":"2013","unstructured":"Ledwidge, M. et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310, 66\u201374 (2013).","journal-title":"JAMA"},{"key":"2567_CR126","doi-asserted-by":"crossref","unstructured":"Mohebi, R. et al. Effect of 2022 ACC\/aHA\/HFSA criteria on stages of heart failure in a pooled community cohort. J. Am. Coll. Cardiol. 81, 2231\u20132242 (2023).","DOI":"10.1016\/j.jacc.2023.04.007"},{"key":"2567_CR127","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/dc21-1113","volume":"45","author":"AK Wright","year":"2022","unstructured":"Wright, A. K. et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 45, 909\u2013918 (2022).","journal-title":"Diabetes Care"},{"key":"2567_CR128","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","volume":"143","author":"JJV McMurray","year":"2021","unstructured":"McMurray, J. J. V. et al. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation 143, 438\u2013448 (2021).","journal-title":"Circulation"},{"key":"2567_CR129","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","volume":"318","author":"GM Felker","year":"2017","unstructured":"Felker, G. M. et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318, 713\u2013720 (2017).","journal-title":"JAMA"},{"key":"2567_CR130","doi-asserted-by":"publisher","first-page":"e006749","DOI":"10.1161\/CIRCHEARTFAILURE.119.006749","volume":"13","author":"M Nayor","year":"2020","unstructured":"Nayor, M. et al. Aptamer-based proteomic platform identifies novel protein predictors of incident heart failure and echocardiographic traits. Circ. Heart Fail. 13, e006749 (2020).","journal-title":"Circ. Heart Fail."},{"key":"2567_CR131","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/CIRCULATIONAHA.122.061481","volume":"146","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Aptamer proteomics for biomarker discovery in heart failure with reduced ejection fraction. Circulation 146, 1411\u20131414 (2022).","journal-title":"Circulation"},{"key":"2567_CR132","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5334\/gh.1141","volume":"17","author":"J Tromp","year":"2022","unstructured":"Tromp, J. et al. World Heart Federation roadmap for digital health in cardiology. Glob. Heart 17, 61 (2022).","journal-title":"Glob. Heart"},{"key":"2567_CR133","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s11897-009-0039-z","volume":"6","author":"PB Adamson","year":"2009","unstructured":"Adamson, P. B. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr. Heart Fail. Rep. 6, 287\u2013292 (2009).","journal-title":"Curr. Heart Fail. Rep."},{"key":"2567_CR134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41569-020-00445-9","volume":"18","author":"C Krittanawong","year":"2021","unstructured":"Krittanawong, C. et al. Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management. Nat. Rev. Cardiol. 18, 75\u201391 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"2567_CR135","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","volume":"387","author":"WT Abraham","year":"2016","unstructured":"Abraham, W. T. et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387, 453\u2013461 (2016).","journal-title":"Lancet"},{"key":"2567_CR136","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jchf.2016.12.011","volume":"5","author":"JP Boehmer","year":"2017","unstructured":"Boehmer, J. P. et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE Study. JACC Heart Fail. 5, 216\u2013225 (2017).","journal-title":"JACC Heart Fail."},{"key":"2567_CR137","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jacc.2017.08.010","volume":"70","author":"MM Givertz","year":"2017","unstructured":"Givertz, M. M. et al. Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J. Am. Coll. Cardiol. 70, 1875\u20131886 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR138","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cardfail.2022.03.349","volume":"28","author":"AF Hernandez","year":"2022","unstructured":"Hernandez, A. F. et al. Multiple cArdiac seNsors for mAnaGEment of heart failure (MANAGE-HF)\u2014phase I evaluation of the integration and safety of the HeartLogic multisensor algorithm in patients with heart failure. J. Card. Fail. 28, 1245\u20131254 (2022).","journal-title":"J. Card. Fail."},{"key":"2567_CR139","doi-asserted-by":"publisher","first-page":"e17957","DOI":"10.2196\/17957","volume":"8","author":"N Subedi","year":"2020","unstructured":"Subedi, N., Rawstorn, J. C., Gao, L., Koorts, H. & Maddison, R. Implementation of telerehabilitation interventions for the self-management of cardiovascular disease: systematic review. JMIR Mhealth Uhealth. 8, e17957 (2020).","journal-title":"JMIR Mhealth Uhealth."},{"key":"2567_CR140","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","volume":"79","author":"L Ghazi","year":"2022","unstructured":"Ghazi, L. et al. Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial. J. Am. Coll. Cardiol. 79, 2203\u20132213 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR141","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jacc.2023.02.005","volume":"81","author":"A Mukhopadhyay","year":"2023","unstructured":"Mukhopadhyay, A. et al. Cluster-randomized trial comparing ambulatory decision support tools to improve heart failure care. J. Am. Coll. Cardiol. 81, 1303\u20131316 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2567_CR142","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2211680","volume":"388","author":"DS Lee","year":"2023","unstructured":"Lee, D. S. et al. Trial of an intervention to improve acute heart failure outcomes. N. Engl. J. Med. 388, 22\u201332 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR143","doi-asserted-by":"publisher","first-page":"k1450","DOI":"10.1136\/bmj.k1450","volume":"361","author":"KS Taylor","year":"2018","unstructured":"Taylor, K. S. et al. Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis. BMJ 361, k1450 (2018).","journal-title":"BMJ"},{"key":"2567_CR144","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10554-020-02046-6","volume":"37","author":"M Schneider","year":"2021","unstructured":"Schneider, M. et al. A machine learning algorithm supports ultrasound-naive novices in the acquisition of diagnostic echocardiography loops and provides accurate estimation of LVEF. Int. J. Cardiovasc Imaging 37, 577\u2013586 (2021).","journal-title":"Int. J. Cardiovasc Imaging"},{"key":"2567_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34245-1","volume":"13","author":"J Tromp","year":"2022","unstructured":"Tromp, J. et al. A formal validation of a deep learning-based automated workflow for the interpretation of the echocardiogram. Nat. Commun. 13, 6776 (2022).","journal-title":"Nat. Commun."},{"key":"2567_CR146","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2589-7500(21)00235-1","volume":"4","author":"J Tromp","year":"2022","unstructured":"Tromp, J. et al. Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. Lancet Digit Health 4, e46\u2013e54 (2022).","journal-title":"Lancet Digit Health"},{"key":"2567_CR147","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.118.034338","volume":"138","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Fully automated echocardiogram interpretation in clinical practice. Circulation 138, 1623\u20131635 (2018).","journal-title":"Circulation"},{"key":"2567_CR148","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ejhf.470","volume":"18","author":"C Klersy","year":"2016","unstructured":"Klersy, C. et al. Effect of telemonitoring of cardiac implantable electronic devices on healthcare utilization: a meta-analysis of randomized controlled trials in patients with heart failure. Eur. J. Heart Fail. 18, 195\u2013204 (2016).","journal-title":"Eur. J. Heart Fail."},{"key":"2567_CR149","unstructured":"American Heart Association. IMPLEMENT-HF. Accessed on 15 May 2023 https:\/\/www.heart.org\/-\/media\/Files\/Professional\/Quality-Improvement\/Get-With-the-Guidelines\/Get-With-The-Guidelines-HF\/Implement-HF\/AHA-IMPLEMENT-HF-Infographic.pdf (2021)."},{"key":"2567_CR150","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1001\/jama.2021.8844","volume":"326","author":"AD DeVore","year":"2021","unstructured":"DeVore, A. D. et al. Effect of a hospital and postdischarge quality improvement intervention on clinical outcomes and quality of care for patients With heart failure with reduced ejection fraction: the CONNECT-HF randomized clinical trial. JAMA 326, 314\u2013323 (2021).","journal-title":"JAMA"},{"key":"2567_CR151","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1177\/2047487319832394","volume":"26","author":"I Frederix","year":"2019","unstructured":"Frederix, I. et al. ESC e-Cardiology Working Group Position Paper: overcoming challenges in digital health implementation in cardiovascular medicine. Eur. J. Prev. Cardiol. 26, 1166\u20131177 (2019).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"2567_CR152","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-021-00548-x","volume":"18","author":"MR Cowie","year":"2021","unstructured":"Cowie, M. R. & Lam, C. S. P. Remote monitoring and digital health tools in CVD management. Nat. Rev. Cardiol. 18, 457\u2013458 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"2567_CR153","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","volume":"314","author":"JN Cohn","year":"1986","unstructured":"Cohn, J. N. et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a veterans administration cooperative study. N. Engl. J. Med. 314, 1547\u20131552 (1986).","journal-title":"N. Engl. J. Med."},{"key":"2567_CR154","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMp1410241","volume":"371","author":"CA Sacks","year":"2014","unstructured":"Sacks, C. A., Jarcho, J. A. & Curfman, G. D. Paradigm shifts in heart-failure therapy\u2014a timeline. N. Engl. J. Med. 371, 989\u2013991 (2014).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02567-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02567-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02567-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:06:23Z","timestamp":1697436383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02567-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":154,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2567"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02567-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has received consulting fees from Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma, EchoNous, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development, Medscape\/WebMD Global, Merck, Novartis, Novo Nordisk, Prosciento, Quidel Corporation, Radcliffe Group, Recardio, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and is a cofounder and nonexecutive director of Us2.ai. The employer of K.F.D., the University of Glasgow, has been remunerated by AstraZeneca for work relating to clinical trials. K.F.D. has received speaker\u2019s honoraria from AstraZeneca, Pharmacosmos and Radcliffe Cardiology, has served on an advisory board for Us2.ai and Bayer AG, served on a clinical endpoint committee for Bayer AG, and has received grant support from Boehringer Ingelheim, Roche Diagnostics and AstraZeneca (paid to the institution of K.F.D.). J.E.H. is supported by National Institutes of Health grants R01 HL134893, R01 HL140224, R01HL160003 and K24 HL153669. J.E.H. has also received past research funding from Bayer, AG. J.J.V.M. has received support from a British Heart Foundation Centre of Research Excellence Grant RE\/18\/6\/34217 and the Vera Melrose Heart Failure Research Fund; has received payments through Glasgow University from work on clinical trials, consulting and other activities from Amgen, AstraZeneca, Bayer, Cardurion, Cytokinetics, GlaxoSmithKline, KBP Biosciences and Novartis; has received personal consulting fees from Alnylam Pharma, Bayer, Bristol Myers Squibb, George Clinical PTY, Ionis Pharma, Novartis, Regeneron Pharma and River 2 Renal; has received personal lecture fees from Abbott, Alkem Metabolics, AstraZeneca, Blue Ocean Scientific Solutions, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge, Emcure Pharma, Eris Lifesciences, European Academy of CME, Hikma Pharmaceuticals, Imagica Health, Intas Pharma, J.B. Chemicals and Pharma, Lupin Pharma, Medscape\/theheart.org, ProAdWise Communications, Radcliffe Cardiology, Sun Pharma, The Corpus, Translation Research Group and Translational Medicine Academy; and is a director of Global Clinical Trial Partners. P.L.M. has received research support from AstraZeneca and received consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Novartis, Novo Nordisk, Orion Pharma, Pharmacosmos, Sanofi, Us2.ai and Vifor. T.O. has received research support from Abbott Diagnostics, ChromaDex, Novartis and Roche Diagnostics; consulting fees and\/or speaker honoraria from Abbott Diagnostics, Bayer, CardiNor and Roche Diagnostics; and stock and stock options from CardiNor.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}